Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 12
Submit an article Journal homepage
119
Views
1
CrossRef citations to date
0
Altmetric
Letter

Chronic myelogenous leukemia diagnosed in two patients with breast cancer

Sara Abu-GhanemDepartment of Oncology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
,
Anat RabinovichDepartment of Hematology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
,
Bertha DelgadoDepartment of Pathology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
,
Daniel BenharrochDepartment of Pathology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
,
Samuel AriadDepartment of Oncology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
,
Itai LeviDepartment of Hematology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
&
David B. GeffenDepartment of Oncology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, IsraelCorrespondence[email protected]
 show all
Pages 2399-2401 | Received 06 May 2011, Accepted 22 Jun 2011, Published online: 18 Aug 2011

References

  • Smith RE, Bryant J, DeCillis A, . Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21: 1195–1204.
  • Romond EH, Perez EA, Bryant J, . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673–1684.
  • Martin M, Villar A, Sole-Calvo A. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1,21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v.CMF regimen, day 1,21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 2003;14: 833–842.
  • Kantarjian HM, Giles F, Quitas-Cardama A, . Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007;13:1089–1097.
  • Quintas-Cardema A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:973–988.
  • Lichtman MA. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia? Oncologist 2008;13:645–654.
  • Surveillance, Epidemiology and End Results Fast Stats. Available from: http://seer.gov/faststats/selections.php
  • Roychoudhuri R, Evans H, Robinson D, . Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004;91:868–872.
  • Kaplan HG, Malmgren JA, Atwood M. Leukemia incidence following primary breast carcinoma treatment. Cancer 2004;101:1529–1536.
  • Rubino C, de Vathaire F, Shamsaldin A, . Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003;89:840–846.
  • Howard RA, Gilbert ES, Chen BE, : Leukemia following breast cancer: an international population-based study of 376,825 women. Breast Cancer Res Treat 2007;105:359–368.
  • Verkooijen HM, Fioretta G, Rapiti E, . Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: results from a population-based study. Int J Cancer 2008;122:1114–1117.
  • Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 2007;99:183–186.
  • Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357:39–51.
  • Bühring HJ, Sures I, Jallal B, . The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood 1995;86:1916–1923.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.